AR057964A1 - Polimorfos de un inhibidor de c-met/hgfr - Google Patents

Polimorfos de un inhibidor de c-met/hgfr

Info

Publication number
AR057964A1
AR057964A1 ARP060105349A ARP060105349A AR057964A1 AR 057964 A1 AR057964 A1 AR 057964A1 AR P060105349 A ARP060105349 A AR P060105349A AR P060105349 A ARP060105349 A AR P060105349A AR 057964 A1 AR057964 A1 AR 057964A1
Authority
AR
Argentina
Prior art keywords
polymorphes
met
hgfr inhibitor
polymorphs
mammals
Prior art date
Application number
ARP060105349A
Other languages
English (en)
Inventor
Jingrog Jean Cui
Michelle Bich Tran-Duble
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR057964A1 publication Critical patent/AR057964A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a polimorfos de (R)-3-[1-(2,6-dicloro-3-fluoro-fenil)-etoxi]-5-(1-piperidin-4-il-1H-pirazol-4-il)-piridin-2-ilamina que son utiles en el tratamiento del crecimiento celular anormal, tal como cáncer, en mamíferos. La presente también se refiere a composiciones que incluyen tales sales y polimorfos, y a métodos de uso de tales composiciones en el tratamiento del crecimiento celular anormal en mamíferos, especialmente seres humanos.
ARP060105349A 2005-12-05 2006-12-04 Polimorfos de un inhibidor de c-met/hgfr AR057964A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74267605P 2005-12-05 2005-12-05

Publications (1)

Publication Number Publication Date
AR057964A1 true AR057964A1 (es) 2007-12-26

Family

ID=38123249

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105349A AR057964A1 (es) 2005-12-05 2006-12-04 Polimorfos de un inhibidor de c-met/hgfr

Country Status (20)

Country Link
US (1) US8217057B2 (es)
EP (1) EP1963302B1 (es)
JP (1) JP4663619B2 (es)
KR (1) KR101146852B1 (es)
CN (1) CN101326175B (es)
AR (1) AR057964A1 (es)
AU (1) AU2006323025B2 (es)
CA (1) CA2632283C (es)
DK (1) DK1963302T3 (es)
ES (1) ES2402419T3 (es)
HK (1) HK1126477A1 (es)
IL (1) IL191971A (es)
NZ (1) NZ568289A (es)
PL (1) PL1963302T3 (es)
PT (1) PT1963302E (es)
RU (1) RU2387650C2 (es)
SI (1) SI1963302T1 (es)
TW (1) TWI389902B (es)
WO (1) WO2007066185A2 (es)
ZA (1) ZA200804374B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01788B (me) * 2004-08-26 2011-02-28 Pfizer Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
EP1959955B1 (en) * 2005-12-05 2010-11-17 Pfizer Products Inc. Method of treating abnormal cell growth
WO2009099982A1 (en) * 2008-02-04 2009-08-13 Osi Pharmaceuticals, Inc. 2-aminopyridine kinase inhibitors
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
JP2012509342A (ja) * 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
CA2796967C (en) 2010-05-04 2015-12-01 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
WO2011143646A1 (en) 2010-05-14 2011-11-17 OSI Pharmaceuticals, LLC Fused bicyclic kinase inhibitors
AR081039A1 (es) 2010-05-14 2012-05-30 Osi Pharmaceuticals Llc Inhibidores biciclicos fusionados de quinasa
CA2808210C (en) * 2010-08-20 2019-10-01 Chugai Seiyaku Kabushiki Kaisha Tetracyclic compounds having alk inhibitory activity and compositions thereof
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US20140088114A1 (en) 2011-05-16 2014-03-27 OSI Pharmaceuticals ,LLC Fused bicyclic kinase inhibitors
TW201306866A (zh) 2011-06-30 2013-02-16 Genentech Inc 抗－ｃ－ｍｅｔ抗體調配物
EP2620140A1 (en) 2012-01-26 2013-07-31 ratiopharm GmbH Crizotinib containing compositions
MD4590C1 (ro) 2012-03-06 2019-03-31 Pfizer Inc. Derivaţi macrociclici pentru tratamentul bolilor proliferative
WO2013181251A1 (en) 2012-05-29 2013-12-05 Ratiopharm Gmbh Crizotinib hydrochloride salt in crystalline
ES2633864T3 (es) 2012-09-24 2017-09-25 Ventana Medical Systems, Inc. Procedimiento para identificar cáncer de pulmón de células no pequeñas que responde al tratamiento usando quinasa de linfoma anaplásico (alk) como marcador
WO2014115169A2 (en) * 2013-01-24 2014-07-31 Hetero Research Foundation Crizotinib solid dispersion
US20160280798A1 (en) 2013-11-06 2016-09-29 The United States Of America, As Represented By The Secretary Department Of Health & Human Service Alk antibodies, conjugates, and chimeric antigen receptors, and their use
CN107002119A (zh) 2014-03-24 2017-08-01 豪夫迈·罗氏有限公司 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联
JP5859712B1 (ja) 2014-04-25 2016-02-10 中外製薬株式会社 ４環性化合物を高用量含有する製剤
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
RU2684278C1 (ru) * 2015-04-23 2019-04-05 Чиа Тай Тяньцин Фармасьютикал Груп Ко., Лтд Фумарат пиридиламина и его кристаллы
EP3287463A4 (en) 2015-04-24 2018-07-11 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
IL292302B2 (en) 2016-05-20 2023-10-01 Biohaven Pharm Holding Co Ltd Use of glutamate modulating factors in cancer immunotherapy
TWI646094B (zh) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
CN108727337A (zh) * 2018-07-03 2018-11-02 无锡富泽药业有限公司 一种克唑替尼中间体的制备方法
BR112021018168B1 (pt) 2019-03-21 2023-11-28 Onxeo Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JPH07109260A (ja) 1993-10-12 1995-04-25 Fuji Photo Film Co Ltd ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
DE60114153T2 (de) 2000-02-16 2006-07-06 Neurogen Corp., Branford Substituierte arylpyrazine
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
OA13151A (en) 2003-02-26 2006-12-13 Sugen Inc Aminoheteroaryl compounds as protein kinase inhibitors.
EA011725B1 (ru) * 2004-08-26 2009-04-28 Пфайзер Инк. Пиразолзамещённые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
ME01788B (me) * 2004-08-26 2011-02-28 Pfizer Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza
CA2578075A1 (en) 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
EP1959955B1 (en) * 2005-12-05 2010-11-17 Pfizer Products Inc. Method of treating abnormal cell growth

Also Published As

Publication number Publication date
CN101326175B (zh) 2012-07-18
US20080293769A1 (en) 2008-11-27
NZ568289A (en) 2011-06-30
AU2006323025B2 (en) 2012-07-05
WO2007066185A2 (en) 2007-06-14
IL191971A (en) 2013-05-30
PT1963302E (pt) 2013-04-09
RU2008120338A (ru) 2010-01-20
AU2006323025A1 (en) 2007-06-14
PL1963302T3 (pl) 2013-06-28
EP1963302A2 (en) 2008-09-03
EP1963302B1 (en) 2013-02-27
IL191971A0 (en) 2011-08-01
DK1963302T3 (da) 2013-04-02
US8217057B2 (en) 2012-07-10
SI1963302T1 (sl) 2013-04-30
CA2632283A1 (en) 2007-06-14
HK1126477A1 (en) 2009-09-04
BRPI0619420A2 (pt) 2011-10-04
JP4663619B2 (ja) 2011-04-06
JP2007153893A (ja) 2007-06-21
TWI389902B (zh) 2013-03-21
KR101146852B1 (ko) 2012-05-16
ES2402419T3 (es) 2013-05-03
ZA200804374B (en) 2009-12-30
RU2387650C2 (ru) 2010-04-27
WO2007066185A3 (en) 2008-01-24
TW200730522A (en) 2007-08-16
KR20080074950A (ko) 2008-08-13
CA2632283C (en) 2011-06-21
CN101326175A (zh) 2008-12-17

Similar Documents

Publication Publication Date Title
AR057964A1 (es) Polimorfos de un inhibidor de c-met/hgfr
CO6531430A2 (es) Tratamiento de cáncer de antagonistas notch 1 resistentes utilizando antagonistas notch3
BR112015018783A2 (pt) mistura íntima seca, composição, método de preparação de uma mistura íntima seca e método de aumento da germinação, crescimento, metabolismo e/ou atividade enzimática de esporos bacterianos
AR056832A1 (es) Procedimiento para tratar el crecimiento celular anormal
AR063127A1 (es) Metodo para la produccion de semilla de maiz hibrido y composiciones producidas a partir del mismo
CO6382157A2 (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
TN2010000305A1 (en) Pyrrolopyrimidines and pyrrolopyridines
PH12018501678A1 (en) Decitabine derivative formulation
CO2017003011A2 (es) Derivados de benzodiazepina citotóxicos
ECSP099803A (es) Derivados de bencimidazol
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
PA8740901A1 (es) Compuestos organicos
TN2010000167A1 (en) Organic compounds
CL2009000651A1 (es) Forma anhidra ii, forma hemi pentahidrato y forma solvato metanol de la sal del acido lactico 4-amino-5-fluoro-3-[5-(4-metil piperazin-1-il)1h-benzimidazol-2-il]quinolin-2-(1h)-ona; composición farmacéutica que las comprende; y uso para tratar enfermedades que inhiben la actividad de vegfr2 y fgfr3, tales como cáncer.
BR112017028604A2 (pt) forma cristalina de base livre de lorlatinibe
MX2010005867A (es) Polimorfos de un inhibidor de c-met/hgfr.
CL2009000957A1 (es) Compuestos derivados de pirrolo[2,3-d]pirimidina; inhibidores de limk2; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos inflamatorios, glaucoma, neurodegeneracion, entre otras.
UY32009A (es) 5-alquinil-pirimidinas
ECSP11010816A (es) Nuevos Compuestos
CL2011001152A1 (es) Compuesto cristalino 6-((s)-1-(6-(1-metil-1h-pirazol-4-il)-[1,2,4]triazolo[3,4-b][1,3,4]tiadiazol-3-il)etil)quinolina, inhibidor de la proteina kinasa c-met; composicion farmaceutica; y metodo para tratar o disminuir la gravedad de un trastorno proliferativo tal como cancer metastasico de colon, mama y hepatico, entre otros.
UY29361A1 (es) Pirroles e imidazoles sustituídos, composiciones que los contienen, procedimiento de fabricación y utilización
ZA200803420B (en) Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases
CO6290768A2 (es) Tiazolil-dihidro-indazoles
UY32100A (es) Compuestos de triazol, su uso asi, como productos que los contienen

Legal Events

Date Code Title Description
FC Refusal